Abstracts submissions end Friday 12 March 2027. Submit now

d
h
m
s

Abstracts deadline EXTENDED Friday 22 May 2026! Submit now

d
h
m
s
Search

CREATE Medicines is pioneering multi-immune programming with its versatile in vivo CAR platform. Our proprietary mRNA-LNP CARs and targeted receptor/LNP technologies enable direct programming of T cells, NK cells, and myeloid cells within the body. CREATE’s in vivo CAR products have demonstrated first-in-human evidence of uptake, expression, and tolerable repeat dosing.

What sets CREATE apart:

  • Proprietary receptor and RNA engineering, including retrotransposon-mediated stability options
  • First-in-human clinical data confirming mechanism of action
  • Multilineage programming across immune cell types (T, NK, myeloid)
  • Demonstrated tolerability with repeat dosing

Share

Key dates

Registrations
Abstracts

More Partners / Exhibitors

Medac GmbH
R-Pharm Group
Novartis
SK Chemicals
Association of Women in Rheumatology
Samsung Bioepis
Days
Hours
Minutes
Seconds

The countdown is on

Have you registered yet?
Don't miss your chance on being part of APLAR 2026 where live sessions feature the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.

Days
Hours
Minutes
Seconds
Until 11:59PM AEST Friday 24 April, 2026

The countdown is on

Have you submitted your abstract yet?
Don't miss your chance on being part of APLAR 2026 where live sessions feature the latest, best-in-class research and provide an opportunity to connect and stay apprised of the latest developments and innovations in the field.